Deal Value Benchmarks
How to read deal value past the headline.
A defensible framework for deal-value benchmarking — structure, size and timing — applied to pharma M&A and licensing transactions.
"Is this deal pricing within the credible band — and how does ours compare?"
Pharma deal-value benchmarks must be PoS-adjusted, structure-decomposed and geography-segmented. Anything less is anecdote.
Deal value is meaningful only when decomposed and PoS-adjusted. The negotiation team that walks in with a band per layer wins more often than the team carrying a single number.
What we’re seeing in the data.
Structure reveals risk-sharing
Heavy back-loaded milestones reflect acquirer caution.
Geography-specific premiums
US rights price 1.3–2× ex-US for same asset.
Strategic vs financial buyers
Strategic buyers willing to pay 20–40% premium for fit.
Late-stage premia compress
Beyond pivotal data, valuation becomes a peak-share negotiation.
How to think about it.
-
01
Pull comp set
Same TA × phase × modality × geography.
-
02
Decompose total value
Upfront / milestones / royalty / equity.
-
03
Apply PoS to milestones
Realistic NPV.
-
04
Adjust for buyer type
Strategic vs financial.
-
05
Express as range
Defensible bands per layer.
What separates a good answer from a defensible one.
Multi-bidder processes lift premium.
Cost of capital shifts deal pace.
Equity stakes change effective economics.
CVR features increasingly common.
Where the signal comes from.
Common questions.
What’s a "fair" valuation?
A defensible band, not a number — calibrated to PoS, geography, structure and buyer type.
How big is the strategic premium?
20–40% over financial buyers in most pharma deals.
Want this answered on your data?
We build decision systems on top of analyses like this — so the next question takes minutes, not weeks.
Talk to a strategist